Pierre Quartier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3242726/publications.pdf

Version: 2024-02-01

191 papers	15,231 citations	18482 62 h-index	19190 118 g-index
204 all docs	204 docs citations	204 times ranked	13382 citing authors

#	Article	IF	Citations
1	Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry. Journal of Rheumatology, 2022, 49, 398-407.	2.0	15
2	Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. Rheumatology, 2022, , .	1.9	0
3	Systemic Juvenile Idiopathic Arthritis/Pediatric Stillâ€™s Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches. Journal of Clinical Medicine, 2022, 11, 1357.	2.4	6
4	AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. Rheumatology, 2022, 61, 4827-4834.	1.9	8
5	Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation. Blood Advances, 2022, 6, 2444-2451.	5.2	18
6	Human Papilloma Virus Vaccination in Patients with Rheumatic Diseases in France: A Study of Vaccination Coverage and Drivers of Vaccination. Journal of Clinical Medicine, 2022, 11, 4137.	2.4	2
7	Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 567-574.	2.0	9
8	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Openâ€Label, Randomized Study. Arthritis and Rheumatology, 2021, 73, 336-346.	5.6	23
9	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 898-906.	2.0	4
10	From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies. Arthritis and Rheumatology, 2021, 73, 1044-1052.	5.6	13
11	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 1073-1081.	2.0	3
12	Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies. Journal of Clinical Immunology, 2021, 41, 603-609.	3.8	16
13	JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology, 2021, 60, 5801-5808.	1.9	52
14	Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 27.	2.1	7
15	Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches. Journal of Clinical Medicine, 2021, 10, 2934.	2.4	10
16	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity ScoreÂCutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2021, 73, 1966-1975.	5.6	33
17	Immunomodulatory treatment and surgical management of idiopathic uveitis and juvenile idiopathic arthritis-associated uveitis in children: a French survey practice. Pediatric Rheumatology, 2021, 19, 139.	2.1	1
18	Mevalonate Kinase Deficiency: A Cause of Severe Very-Early-Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1853-1857.	1.9	11

#	Article	IF	Citations
19	Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials, 2021, 22, 689.	1.6	26
20	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNÎ³) Monoclonal Antibody. Blood, 2021, 138, 2058-2058.	1.4	5
21	A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report. Pediatric Rheumatology, 2021, 19, 168.	2.1	3
22	Pourquoi le clinicien est-il en difficultÃ© devant lâ€™adolescent prÃ©sentant une douleur musculo-squelettique chronique fonctionnelle ? Une Ã©tude qualitative. Perspectives Psy, 2021, 60, 235-242.	0.1	0
23	Circulating Interferonâ€Î± Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et al. Arthritis and Rheumatology, 2020, 72, 195-197.	5.6	15
24	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Sevenâ€Year Interim Results. Arthritis Care and Research, 2020, 72, 1420-1430.	3.4	17
25	Inhibition of IFNÎ± secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. Rheumatology, 2020, 59, 1171-1174.	1.9	5
26	Comment on: Monogenic mimics of BehÃ§etâ€™s disease in the young. Rheumatology, 2020, 59, e109-e111.	1.9	1
27	Severe Abdominal Manifestations in Juvenile Dermatomyositis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 247-251.	1.8	12
28	Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-Î± signalling. Rheumatology, 2020, 59, 1927-1937.	1.9	26
29	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Openâ€Label, Activeâ€Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5.6	21
30	Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab â€“ a real-world experience. Seminars in Arthritis and Rheumatism, 2020, 50, 744-748.	3.4	2
31	Tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis. Lancet Rheumatology, The, 2020, 2, e122-e123.	3.9	3
32	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2â€“5â€‰years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology, 2020, 18, 19.	2.1	15
33	Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Annals of Intensive Care, 2020, 10, 69.	4.6	247
34	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.8	3
35	A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. Journal of Clinical Immunology, 2019, 39, 702-712.	3.8	3
36	Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Antiâ€Interleukinâ€1 Treatments. JBMR Plus, 2019, 3, e10185.	2.7	9

#	Article	IF	Citations
37	Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagementâ€"A new target for lupus treatment. Science Advances, 2019, 5, eaav9019.	10.3	34
38	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
39	Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opinion on Biological Therapy, 2019, 19, 477-490.	3.1	51
40	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
41	OP0055â€…EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
42	AB1071â€…AUTO-IMMUNE AND INFLAMMATORY DISEASES IN CHILDREN WITH SICKLE CELL DISEASE: DIAGNOSTIC AND THERAPEUTIC ISSUES. , 2019, , .		0
43	FRI0549â€…SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY. , 2019, , .		2
44	Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open, 2019, 5, e000933.	3.8	29
45	Anakinra in children and adults with Stillâ€™s disease. Rheumatology, 2019, 58, vi9-vi22.	1.9	75
46	Chronic idiopathic musculoskeletal pain in youth: a qualitative study. Pediatric Rheumatology, 2019, 17, 86.	2.1	8
47	Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. Current Opinion in Ophthalmology, 2019, 30, 179-186.	2.9	16
48	Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism, 2019, 48, 1014-1018.	3.4	7
49	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. Journal of Clinical Rheumatology, 2019, 25, e40-e42.	0.9	3
50	Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?. Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216827.	0.9	3
51	Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology, 2018, 57, 873-879.	1.9	44
52	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
53	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.9	183
54	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. Journal of Rheumatology, 2018, 45, 425-429.	2.0	23

#	Article	IF	Citations
55	ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Annals of the Rheumatic Diseases, 2018, 77, 1003-1011.	0.9	110
56	Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clinical Immunology, 2018, 188, 52-57.	3.2	53
57	Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatric Rheumatology, 2018, 16, 21.	2.1	49
58	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	3.0	0
59	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	3.0	0
60	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched caseâ€“control study from the French Vasculitis Study Group Registry. Autoimmunity Reviews, 2018, 17, 108-114.	5.8	42
61	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719.	0.9	79
62	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
63	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
64	Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges. Pediatric Rheumatology, 2018, 16, 5.	2.1	22
65	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. Autoimmunity Reviews, 2018, 17, 984-989.	5.8	15
66	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clinical and Experimental Rheumatology, 2018, 36, 668-675.	0.8	31
67	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clinical and Experimental Rheumatology, 2018, 36, 920-928.	0.8	8
68	Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP). American Journal of Hematology, 2017, 92, E79-E81.	4.1	7
69	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
70	Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2017, 140, 1388-1393.e8.	2.9	222
71	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
72	Detection of interferon alpha protein reveals differential levels and cellular sources in disease. Journal of Experimental Medicine, 2017, 214, 1547-1555.	8.5	288

#	Article	IF	Citations
73	Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. Journal of Clinical Immunology, 2017, 37, 123-132.	3.8	163
74	Protein kinase D at the Golgi controls NLRP3 inflammasome activation. Journal of Experimental Medicine, 2017, 214, 2671-2693.	8.5	197
75	Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. Rheumatology, 2017, 56, 1814-1816.	1.9	7
76	A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet Journal of Rare Diseases, 2017, 12, 54.	2.7	32
77	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy, 2017, 19, 13.	3.5	49
78	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptorâ€“Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	3.4	75
79	Realâ€World Experience and Impact of Canakinumab in Cryopyrinâ€Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care and Research, 2017, 69, 903-911.	3.4	14
80	Type I interferon-mediated autoinflammation due to DNase II deficiency. Nature Communications, 2017, 8, 2176.	12.8	164
81	Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4578-4587.	3.6	5
82	Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology, 2016, 55, kev359.	1.9	21
83	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
84	Antiâ€“tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study. Epilepsia, 2016, 57, 956-966.	5.1	67
85	Ã‰tude randomisÃ©e en double insu testant lâ€™anticorps anti-TNF alpha adalimumab contre placebo dans lâ€™uvÃ©ite de lâ€™arthrite juvÃ©nile idiopathique (Ã‰tude ADJUVITE). Revue Du Rhumatisme (Edition Francaise), 2016, 83, A115.	0.0	0
86	LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis. Clinical Immunology, 2016, 168, 88-93.	3.2	57
87	Ã‰volution Ã long terme des enfants atteints de forme pÃ©diatrique de pÃ©riartÃ©rite noueuse cutanÃ©e et viscÃ©rale. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 194-200.	0.0	0
88	Choice of biologic drug among children with juvenile idiopathic arthritis. Rheumatology, 2016, 55, 1534-1535.	1.9	4
89	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2016, 11, 141.	2.7	62
90	Impact de lâ€™arthrite juvÃ©nile idiopathique sur la qualitÃ© de vie pendant la pÃ©riode de transition Ã lâ€™Ã¢ge adulte Ã lâ€™Ã¨re des biothÃ©rapies. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 281-286.	0.0	0

#	Article	IF	Citations
91	Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. Joint Bone Spine, 2016, 83, 369-371.	1.6	17
92	Impact of juvenile idiopathic arthritis on quality of life during transition period at the era of biotherapies. Joint Bone Spine, 2016, 83, 69-74.	1.6	25
93	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	13.7	168
94	Foveal Serous Retinal Detachment in Juvenile Idiopathic Arthritis-associated Uveitis. Ocular Immunology and Inflammation, 2016, 24, 386-391.	1.8	8
95	ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open, 2016, 2, e000236.	3.8	47
96	Musculoskeletal Symptoms in Patients With Cryopyrinâ€Associated Periodic Syndromes: A Large Database Study. Arthritis and Rheumatology, 2015, 67, 3027-3036.	5.6	24
97	Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-Î³. Rheumatology, 2015, 54, 1507-1517.	1.9	125
98	Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa. Joint Bone Spine, 2015, 82, 251-257.	1.6	21
99	Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 706-711.	2.0	85
100	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
101	Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. Current Opinion in Immunology, 2015, 32, 90-105.	5.5	69
102	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
103	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.9	180
104	A Large National Cohort of French Patients With Chronic Recurrent Multifocal Osteitis. Arthritis and Rheumatology, 2015, 67, 1128-1137.	5.6	178
105	Brief Report: Childhoodâ€Onset Systemic Necrotizing Vasculitides: Longâ€Term Data From the French Vasculitis Study Group Registry. Arthritis and Rheumatology, 2015, 67, 1959-1965.	5.6	47
106	Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i104-12.	0.7	45
107	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.9	251
108	Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open, 2015, 1, e000036-e000036.	3.8	42

#	Article	IF	Citations
109	Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 128-135.	2.0	28
110	Share â€“ Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	2.1	0
111	Inborn errors of metabolism underlying primary immunodeficiencies. Journal of Clinical Immunology, 2014, 34, 753-771.	3.8	27
112	A152: Safety and Effectiveness of Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 to 4 Years. Arthritis and Rheumatology, 2014, 66, S196-S197.	5.6	0
113	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. Arthritis and Rheumatology, 2014, 66, S5-S6.	5.6	4
114	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.9	92
115	Disease of the Year: Juvenile Idiopathic Arthritis-associated Uveitisâ€"Classification and Diagnostic Approach. Ocular Immunology and Inflammation, 2014, 22, 56-63.	1.8	36
116	Clinical features of childhood granulomatosis with polyangiitis (wegenerâ€™s granulomatosis). Pediatric Rheumatology, 2014, 12, 18.	2.1	85
117	Genetic association with articular damage in patients with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2014, 12, .	2.1	0
118	MRI assessment of tenosynovitis in children with juvenile idiopathic arthritis: inter- and intra-observer variability. Pediatric Radiology, 2013, 43, 796-802.	2.0	20
119	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 666-669.	2.0	17
120	Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacology & Toxicology, 2013, 14, 40.	2.4	49
121	The identification of MAFB mutations in eight patients with multicentric carpoâ€"tarsal osteolysis supports genetic homogeneity but clinical variability. American Journal of Medical Genetics, Part A, 2013, 161, 3023-3029.	1.2	30
122	The lung is involved in juvenile dermatomyositis. Pediatric Pulmonology, 2013, 48, 1016-1025.	2.0	26
123	Mutation in the SLC29A3 Gene: A New Cause of a Monogenic, Autoinflammatory Condition. Pediatrics, 2013, 131, e1308-e1313.	2.1	64
124	Juvenile dermatomyositis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1457-1463.	1.8	13
125	Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology, 2013, 52, 267-275.	1.9	45
126	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.9	109

#	Article	IF	Citations
127	RNA recognition by human TLR8 can lead to autoimmune inflammation. Journal of Experimental Medicine, 2013, 210, 2903-2919.	8.5	167
128	Radiological Peripheral Involvement in a Cohort of Patients with Polyarticular Juvenile Idiopathic Arthritis at Adulthood. Journal of Rheumatology, 2013, 40, 520-527.	2.0	14
129	Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology, 2012, 51, 1855-1859.	1.9	112
130	Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nature Immunology, 2012, 13, 1178-1186.	14.5	410
131	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406.	27.0	588
132	ANCA-Associated Glomerulonephritis in Systemic-Onset Juvenile Idiopathic Arthritis. American Journal of Kidney Diseases, 2012, 59, 439-443.	1.9	10
133	Morphologic and immunohistochemical characterization ofÂgranulomas in the nucleotide oligomerization domain 2â€“related disorders Blau syndrome and Crohn disease. Journal of Allergy and Clinical Immunology, 2012, 129, 1076-1084.	2.9	64
134	Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatology International, 2012, 32, 711-716.	3.0	45
135	A phase II, multicenter, openâ€label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 2012, 64, 557-567.	6.7	167
136	Cataract surgery with primary intraocular lens implantation in children with uveitis: Long-term outcomes. Journal of Cataract and Refractive Surgery, 2011, 37, 1977-1983.	1.5	43
137	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. Open Access Rheumatology: Research and Reviews, 2011, 3, 9.	1.6	6
138	Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature. Seminars in Arthritis and Rheumatism, 2011, 41, 265-271.	3.4	178
139	Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. Journal of Ophthalmic Inflammation and Infection, 2011, 1, 133-136.	2.2	23
140	The emerging role of interleukinâ€1Î² in autoinflammatory diseases. Arthritis and Rheumatism, 2011, 63, 314-324.	6.7	82
141	A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Annals of the Rheumatic Diseases, 2011, 70, 747-754.	0.9	462
142	Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry. Journal of Rheumatology, 2011, 38, 1436-1440.	2.0	77
143	Mevalonate Kinase Deficiency: A Survey of 50 Patients. Pediatrics, 2011, 128, e152-e159.	2.1	195
144	Current treatments for juvenile idiopathic arthritis. Joint Bone Spine, 2010, 77, 511-516.	1.6	31

#	Article	IF	Citations
145	Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: A case report. Arthritis Care and Research, 2010, 62, 1346-1350.	3.4	15
146	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	3.4	84
147	Abatacept improves healthâ€related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care and Research, 2010, 62, 1542-1551.	3.4	72
148	Longâ€term efficacy of the interleukinâ€1 receptor antagonist anakinra in ten patients with neonatalâ€onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis and Rheumatism, 2010, 62, 258-267.	6.7	239
149	Longâ€term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 1792-1802.	6.7	204
150	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2458-2466.	6.7	352
151	ActualitÃ©s thÃ©rapeutiques des arthrites juvÃ©niles idiopathiques. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT /Ov	0.0	1
152	Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology, 2010, 49, 1694-1698.	1.9	49
153	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.9	187
154	Uveitis Related to Juvenile Idiopathic Arthritis: Familial Cases and Possible Genetic Implication in the Pathogenesis. Ocular Immunology and Inflammation, 2010, 18, 172-177.	1.8	24
155	Sicca syndrome and salivary gland infiltration in children with autoimmune disorders: when can we diagnose SjÃ¶gren syndrome?. Clinical and Experimental Rheumatology, 2010, 28, 434-9.	0.8	15
156	Juvenile Idiopathic Arthritis: Classification, Clinical Presentation and Current Treatments. Hormone Research, 2009, 72, 4-12.	1.8	26
157	Efficacy and safety of TNFÎ± antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine, 2009, 76, 24-27.	1.6	41
158	Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine, 2009, 76, 383-388.	1.6	33
159	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine, 2009, 360, 2416-2425.	27.0	754
160	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet, The, 2008, 372, 383-391.	13.7	486
161	Allogeneic Bone Marrow Transplantation in Mevalonic Aciduria. New England Journal of Medicine, 2007, 356, 2700-2703.	27.0	110
162	Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2567-2573.	3.6	75

#	Article	IF	Citations
163	Infantile Onset Panniculitis with Uveitis and Systemic Granulomatosis: A New Clinicopathologic Entity. Journal of Pediatrics, 2007, 151, 707-709.	1.8	15
164	L'amÃ©lioration des paramÃ¨tres de la croissance staturopondÃ©rale est associÃ©e Ã la rÃ©ponse au traitement par le mÃ©thotrexate chez les enfants atteints d'arthrite juvÃ©nile idiopathique. Revue Du Rhumatisme (Edition Francaise), 2005, 72, 807-812.	0.0	0
165	Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine, 2005, 72, 392-396.	1.6	19
166	Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophagesin vitro. European Journal of Immunology, 2005, 35, 252-260.	2.9	155
167	Primary Cytomegalovirus Infection, Atypical Kawasaki Disease, and Coronary Aneurysms in 2 Infants. Clinical Infectious Diseases, 2005, 41, e53-e56.	5.8	32
168	Evaluation of a peer support group therapy for HIV-infected adolescents. Aids, 2005, 19, 1501-1508.	2.2	112
169	Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clinical Immunology, 2004, 110, 22-29.	3.2	224
170	Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis and Rheumatism, 2003, 48, 1093-1101.	6.7	343
171	Enteroviral Meningoencephalitis after Antiâ€CD20 (Rituximab) Treatment. Clinical Infectious Diseases, 2003, 36, e47-e49.	5.8	106
172	Lupus-Prone Mice Have an Abnormal Response to Thioglycolate and an Impaired Clearance of Apoptotic Cells. Journal of Immunology, 2003, 170, 3223-3232.	0.8	165
173	Autoimmunity in Wiskott-Aldrich Syndrome: Risk Factors, Clinical Features, and Outcome in a Single-Center Cohort of 55 Patients. Pediatrics, 2003, 111, e622-e627.	2.1	294
174	Analysis of TCR, pTÎ±, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood, 2003, 101, 2693-2703.	1.4	152
175	Propionibacterium acnes Chest Infections in Patients with Chronic Granulomatous Disease: Case Reports. Clinical Infectious Diseases, 2002, 34, 853-854.	5.8	12
176	Chronic Infantile Neurological Cutaneous and Articular Syndrome Is Caused by Mutations in CIAS1, a Gene Highly Expressed in Polymorphonuclear Cells and Chondrocytes. American Journal of Human Genetics, 2002, 71, 198-203.	6.2	718
177	Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis. Joint Bone Spine, 2002, 69, 468-481.	1.6	19
178	Immunodeficiency and genetic conditions that cause arthritis in childhood. Current Rheumatology Reports, 2002, 4, 483-493.	4.7	2
179	Validation de la version franÃ§aise du Childhood Health Assessment Questionnaire (CHAQ) dans les arthrites juvÃ©niles idiopathiques. Revue Du Rhumatisme (Edition Francaise), 2002, 69, 898-914.	0.0	6
180	Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2002, 117, 965-972.	2.5	128

#	Article	IF	Citations
181	Severe cardiac involvement in children with systemic sclerosis and myositis. Journal of Rheumatology, 2002, 29, 1767-73.	2.0	40
182	Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet, The, 2001, 358, 1511-1513.	13.7	287
183	Tolerance of efavirenz in children. Aids, 2001, 15, 241-243.	2.2	34
184	Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. British Journal of Haematology, 2001, 115, 112-118.	2.5	125
185	Molecular Basis of a Selective C1s Deficiency Associated with Early Onset Multiple Autoimmune Diseases. Journal of Immunology, 2001, 166, 7612-7616.	0.8	61
186	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood, 2000, 96, 2254-2261.	1.4	63
187	Comparative Tolerability of Treatments for Juvenile Idiopathic Arthritis. BioDrugs, 2000, 14, 159-183.	4.6	10
188	ENTEROVIRAL MENINGOENCEPHALITIS IN X-LINKED AGAMMAGLOBULINEMIA: INTENSIVE IMMUNOGLOBULIN THERAPY AND SEQUENTIAL VIRAL DETECTION IN CEREBROSPINAL FLUID BY POLYMERASE CHAIN REACTION. Pediatric Infectious Disease Journal, 2000, 19, 1106-1108.	2.0	73
189	Haemopoietic stem-cell transplantation for juvenile chronic arthritis. Lancet, The, 1999, 353, 1885-1886.	13.7	34
190	Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. Journal of Pediatrics, 1999, 134, 589-596.	1.8	282
191	Germ-line transcription and methylation status of the TCR-JÎ± locus in its accessible configuration. European Journal of Immunology, 1997, 27, 1619-1625.	2.9	38